Skip to content

EBIT at other companies

Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$34.2M+59.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Celcuity logo
CelcuityCELC
-$50.51M-39.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Calculated from Geron’s reported figures.

Plus components not separately reported this period.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's EBIT?
Geron (GERN) reported EBIT of $158K in Q1 2026.
How has Geron's EBIT changed year-over-year?
Geron's EBIT increased by 100.9% year-over-year, from -$16.7M to $158K.
What is the long-term trend for Geron's EBIT?
Over 4 years (2021 to 2025), Geron's EBIT has grown at a -11.9% compound annual growth rate (CAGR), from -$114M to -$68.59M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.